Nanoparticle Engineering Processes for Enhancing the Dissolution Rates of Poorly Water Soluble Drugs

Drug Development and Industrial Pharmacy

Volumn 30, Issue 3, 2004, Pages 233-245

  Hu, Jiahui ^a   Johnston, Keith P ^b   Williams III, Robert O ^c  

^a FOREST RESEARCH INSTITUTE   (United States)

^b The University of Texas at Austin   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Bioavailability; Dissolution; Drug delivery; EPAS; High pressure homogenization; Nanoparticle; Nanoparticle engineering process; Particle engineering; PCA; Poorly water soluble drug; RESAS; SAS; SEDS; SFL; Solubility; Water insoluble drug; Wet milling

Indexed keywords

CYCLOSPORIN; EXCIPIENT; NANOPARTICLE; SURFACTANT;

AQUEOUS SOLUTION; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG SOLUBILITY; EVAPORATION; IN VITRO STUDY; IN VIVO STUDY; PARTICLE SIZE; PRECIPITATION; REVIEW; SUPERCRITICAL FLUID;

CHEMISTRY, PHYSICAL; NANOTECHNOLOGY; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; PHASE TRANSITION; SOLUBILITY; SOLVENTS; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 1842559836     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120030422     Document Type: Review

References (74)

1. Radtke, M. Pure drug nanoparticles for the formulation of poorly soluble drugs. New Drugs 2001, 3, 62-68.
2. Lipinski, C. Poor aqueous solubility-an industry wide problem in drug delivery. Am. Pharm. Rev. 2002, 5, 82-85.
3. Noyes, A.A.; Whitney, W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 1897, 19, 930-934.
4. Tom, J.W.; Bebenedetti, P.G. Particle formation with supercritical fluids-a review. J. Aerosol Sci. 1991, 22, 555-584.
5. 2 and cryogenic spray-freezing technologies. Drug Dev. Ind. Pharm. 2001, 27, 1003-1015.
6. Pace, S.N.; Pace, G.W.; Parikh, I.; Mishra, A.K. Novel injectable formulations of insoluble drugs. Pharm. Technol. 1999, 3, 116-134.
7. Dressman, J.B.; Reppas, C. In vitro-in vivo correlation for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 2000, 11, S73-S80.
8. Serajuddin, A.T.M. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88, 1058-1066.
9. Merisko-Liversidge, E.; Liversidge, G.G.; Cooper, E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 2003, 18, 113-120.
10. York, P. Strategies for particle design using supercritical fluid technologies. PSTT 1999, 2, 430-440.
11. Cavalli, R.; Gasco, M.R.; Barresi, A.A.; Rovero, G. Evaporative drying of aqueous dispersions of solid lipid nanoparticles. Drug Dev. Ind. Pharm. 2001, 27, 919-924.
12. Rambali, B.; Verreck, G.; Baert, L.; Massart, D.L. Itraconazole formulation studies of the melt-extrusion process with mixture design. Drug Dev. Ind. Pharm. 2003, 29, 641-652.
13. Santhi, K.; Dhanaraj, S.A.; Rajendran, S.D.; Raja, K.; Ponnusankar, S.; Suresh, B. Nonliposomal approach-a study of preparation of egg albumin nanospheres containing amphotericin-B. Drug Dev. Ind. Pharm. 1999, 25, 547-551.
14. Cherian, A.K.; Rana, A.C.; Jain, S.K. Self-assembled carbohydrate-stabilized ceramic nanoparticles for the parenteral delivery of insulin. Drug Dev. Ind. Pharm. 2000, 26, 459-463.
15. Muller, R.H.; Peters, K. Nanosuspensions for the formulation of poorly soluble drugs I. Preparation by a size-reduction technique. Int. J. Pharm. 1998, 160, 229-237.
16. Subramaniam, B.; Rajewski, R.A.; Snavely, K. Pharmaceutical processing with supercritical carbon dioxide. J. Pharm. Sci. 1997, 86, 885-890.
17. Rojanapanthu, P.; Sarisuta, N.; Chaturon, K.; Kraisintu, K. Physicochemical properties of amphotericin b liposomes prepared by reverse-phase evaporation method. Drug Dev. Ind. Pharm. 2003, 29, 31-37.
18. Delie, F. Evaluation of nano- and microparticle uptake by the gastrointestinal tract. Adv. Drug Deliv. Rev. 1998, 34, 221-233.
19. Hoffart, V.; Ubrich, N.; Simonin, C.; Babak, V.; Vigneron, C.; Hoffman, M.; Lecompte, T.; Maincent, P. Low molecular weight heparin-loaded polymeric nanoparticles: formulation, characterization, and release characteristics. Drug Dev. Ind. Pharm. 2002, 28, 1091-1099.
20. Brigger, I.; Dubemet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2002, 54, 631-651.
21. Muller, R.H.; Jacobs, C.; Kayser, O. Nanosuspension as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 2001, 47, 3-19.
22. Pratsinis, S.E.; Vemury, S. Particle formation in gases: a review. Powder Technol. 1996, 88, 267-273.
23. Müller, R.H.; Radtke, M.; Wissing, S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54, S131-S155.
24. Soppimath, K.S.; Aminabhavi, T.M.; Kulkami, A.R.; Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70, 1-20.
25. Panyam, J.; Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 2003, 55, 329-347.
26. York, P.; Shekunov, B.Y. Crystallization processes in pharmaceutical technology and drug delivery design. J. Cryst. Growth 2000, 211, 122-136.
27. Liversidge, G.G.; Cundy, K.C.; Bishop, J.F.; Czekai, D.A. Surface Modified Drug Nanoparticles. US Patent 5,145,684, 1992.
28. Muller, R.H.; Becker, R.; Kruss, B.; Peters, K. Pharmaceutical Nanosuspensions for Medicament Administration as Systems with Increased Saturation Solubility and Rate of Solution. US Patent 5,858,410, 1999.
29. Liversidge, G.G. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int. J. Pharm. 1995, 125, 309-313.
30. Merisko-Liversidge, E.; Sarpotdar, P.; Bruno, J.; Hajj, S.; Wei, L.; Peltier, N.; Rake, J.; Shaw, J.M.; Pugh, S.; Polin, L.; Jones, J.; Corbett, T.; Cooper, E.; Liversidge, G.G. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 1996, 13, 272-278.
31. Liversidge, G.G.; Cundy, K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm. 1995, 125, 91-97.
32. Zheng, J.Y. Sterile filtration of nanocrystal drug formulations. Drug Dev. Ind. Pharm. 1997, 23, 1087-1093.
33. Rawlins, E.A. Bentley's Textbook of Pharmaceutics, 8th Ed.; Bailliere Tindall: London, UK, 1977.
34. Bodmeier, R.; Wang, H.; Dixon, D.J.; Mawson, S.; Johnston, K.P. Polymeric microspheres prepared by spraying into compressed carbon dioxide. Pharm. Res. 1995, 12, 1211-1217.
35. Hu, J.; Rogers, T.L.; Brown, J.N.; Young, T.J.; Johnston, K.P.; Williams, R.O. Improvement of dissolution rates of poorly water soluble APIs using the novel spray freezing into liquid technology. Pharm. Res. 2002, 19, 1278-1284.
36. Dixon, D.J.; Johnston, K.P.; Brodemier, R.A. Polymeric materials formed by precipitation with a compressed fluid antisolvent. AIChE J. 1993, 39, 127-139.
37. Reverchon, E.; Porta, G.D. Production of antibiotic micro- and nano-particles by supercritical antisolvent precipitation. Powder Technol. 1999, 106, 23-29.
38. Chattopadhyay, P.; Gupta, R.B. Protein nanoparticles formation by supercritical antisolvent with enhanced mass transfer. AIChE J. 2002, 48, 235-244.
39. Turk, M.; Hils, P.; Helfgen, B.; Schaber, K.; Martin, H.J.; Wahl, M.A. Micronization of pharmaceutical substances by the rapid expansion of supercritical solutions (RESS): a promising method to improve bioavailability of poorly soluble pharmaceutical agents. J. Supercrit. Fluids 2002, 22, 75-84.
40. Falk, R.; Randolph, T.W.; Meyer, J.D.; Kelley, R.M.; Manning, M.C. Controlled release of ionic compounds from poly(L-lactide) microspheres produced by precipitation with a compressed antisolvent. J. Control. Release 1997, 44, 77-85.
41. Hanna, M.H.; York, P. Method and Apparatus for the Formation of Particles. U.S. Patent 5,851,453, 1998.
42. Steckel, H.; Müller, B.W. Metered-dose inhaler formulation of fluticasone-17-propionate micronized with supercritical carbon dioxide using the alternative propellant HFA-227. Int. J. Pharm. 1998, 173, 25-33.
43. Subramaniam, B.; Saim, S.; Rajewski, R.A.; Stella, V. Method of Particle Precipitation and Coating Using Nearcritical and Supercritical Antisolvents. U.S. Patent 5,833,891, 1997.
44. Young, T.J.; Johnston, K.P.; Mishima, K.; Tanaka, H. Encapsulation of lysozyme in a biodegradable polymer by precipitation with a vapor-over-liquid antisolvent. J. Pharm. Sci. 1999, 88, 640-650.
45. Young, T.J.; Mawson, S.; Johnston, K.P.; Henriksen, I.B.; Pace, G.W.; Mishra, A.K. Rapid expansion from supercritical to aqueous solution to produce submicron suspensions of water-insoluble drugs. Biotechnol. Prog. 2000, 16, 402-407.
46. Henrikson, I.B.; Mishra, A.K.; Pace, G.W.; Johnston, K.P.; Mawson, S. Insoluble Drug Delivery. WO9714407, 1997.
47. Pace, G.W., Vachon, M.G., Mishra, A.K., Henrikson, I.B., Krukonis, V. Processes to GenerateSubmicron Particles of Water-Insoluble Compounds. U.S. Patent 6,177,103, 2001.
48. Briggs, A.R.; Maxwell, T.J. Process for Preparing Powder Blends. U.S. Patent 3,721,725, 1973.
49. Briggs, A.R.; Maxwell, T.J. Lyophilized Biological Products. U.S. Patent 3,928,566, 1975.
50. Briggs, A.R.; Maxwell, T.J. Method of Preparation of Lyophilized Biological Products. U.S. Patent 3,932,943, 1976.
51. Dunn, D.B.; Masavage, G.J., Sauer, H.A. Method of Freezing Solution Droplets and the Like Using Immiscible Refrigerants of Differing Densities. U.S. Patent 3,653,222, 1972.
52. Buxton, I.R.; Peach, J.M. Process and Apparatus for Freezing a Liquid Medium. U.S. Patent 4,470,202, 1984.
53. Sauer, H.A. Method and Apparatus for Freeze-Freeze Drying. U.S. Patent 3,484,946, 1969.
54. Adams, T.H.; Beck, J.P.; Menson, R.C. Method and Apparatus for Making Novel Particulate Composition. U.S. Patent 4,211,015, 1980.
55. Adams, T.H.; Beck, J.P.; Menson, R.C. Novel Particulate Composition. U.S. Patent 4,323,478, 1982.
56. Costantino, H.R.; Firouzabadian, L.; Hogeland, K.; Wu, C.; Beganski, C.; Carrasquillo, K.G.; Córdova, M.; Griebenow, K.; Zale, S.E.; Tracy, M.A. Protein Spray-Freeze Drying. Effect of Atomization Conditions on Particle Size and Stability. Pharm. Res. 2000, 17, 1374-1383.
57. Costantino, H.R.; Firouzabadian, L.; Wu, C.; Carrasquillo, K.G.; Griebenow, K.; Zale, S.E.; Tracy, M.A. Protein spray freeze drying. 2. Effect of formulation variables on particle size and stability. J. Pharm. Sci. 2002, 91, 388-395.
58. Maa, Y.F.; Nguyen, P.A.; Sweeney, T.; Shire, S.J.; Hsu, C.C. Protein inhalation powders-spray drying vs. spray freeze drying. Pharm. Res. 1999, 16, 249-254.
59. Maa, Y.F.; Prestrelski, S.J. Biopharmaceutical powders: particle formation and formulation considerations. Curr. Pharm. Biotechnol. 2000, 1, 283-302.
60. Gombotz, W.R.; Healy, M.S.; Brown, L.R.; Auer, H.E. Process for Producing Small Particles of Biologically Active Molecules. U.S. Patent 5019400, 1990.
61. Gombotz, W.R.; Healy, H.S.; Brown, L.R. Very Low Temperature Casting of Controlled Release Microspheres. WO 90/13285, 1991.
62. Gombotz, W.R.; Pankey, S.C.; Phan, D.; Drager, R.; Donaldson, K.; Antonsen, K.P.; Hoffman, A.S.; Raff, H.V.; Howard, V. The stabilization of a human IgM monoclonal antibody with poly-(vinyl-pyrrolidone). Pharm. Res. 1994, 11, 624-632.
63. Gusman, M.I.; Johnson, S.M. Cryochemical Method of Preparing Ultrafine Particles of High-Purity Superconducting Oxides. U.S. Patent 4,975,415, 1990.
64. Williams, R.O.; Hu, J.; Rogers, T.L.; Barron, M.K.; Young, T.J.; Yu, Z.; Johnston, K.P. Process for Production of Nanoparticles and Microparticles by Spray Freezing into Liquid. U.S. Patent 20030041602, 2003.
65. Hu, J.; Johnston, K.P.; Williams, R.O.I. Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent vs. aqueous-organic co-solvent systems. Eur. J. Pharm. Sci. 2003, 20, 295-303.
66. Hu, J.; Johnston, K.P.; Williams, R.O. Rapid dissolving high potency danazol powders produced by spray freezing into liquid (SFL) process with organic solvents. Int. J. Pharm. 2003, in press.
67. Rogers, T.L.; Hu, J.; Yu, Z.; Johnston, K.P.; Williams, R.O. A novel particle engineering technology: spray-freezing into liquid. Int. J. Pharm. 2002, 242, 93-100.
68. Rogers, T.L.; Nelsen, A.C.; Hu, J.; Brown, J.N.; Sarkari, M.; Young, T.J.; Johnston, K.P.; Williams, R.O. A novel particle engineering technology to enhance dissolution of poorly water soluble drugs: spray-freezing into liquid. Eur. J. Pharm. Biopharm. 2002, 54, 271-280.
69. Rogers, T.L.; Nelsen, A.C.; Sarkari, M.; Young, T.; Johnston, K.P.; Williams, R.O. Enhanced aqueous dissolution of a poorly water soluble drug by novel particle engineering technology: spray-freezing into liquid with atmospheric freeze-drying. Pharm. Res. 2003, 20, 485-493.
70. Rogers, T.L.; Overhoff, K.A.; Shah, P.; Santiago, P.; Yacaman, M.J.; Johnston, K.P.; Williams, R.O. Micronized powders of a poorly water soluble drug produced by a spray-freezing into liquid-emulsion process. Eur. J. Pharm. Biopharm. 2003, 55, 167-172.
71. Yu, Z.; Rogers, T.L.; Hu, J.; Johnston, K.P.; Williams, R.O. Preparation and characterization of microparticles containing peptide produced by novel process: spray freezing into liquid. Eur. J. Pharm. Biopharm. 2002, 54, 221-228.
72. Chen, X.; Young, T.J.; Sarkari, M.; Williams, R.O.; Johnston, K.P. Preparation of cyclosporine A nanoparticles by evaporative precipitation into aqueous solution. Int. J. Pharm. 2002, 242, 3-14.
73. Sarkari, M.; Brown, J.N.; Chen, X.; Swinnea, S.; Williams, R.O.; Johnston, K.P. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int. J. Pharm. 2002, 243, 17-31.
74. Chen, X.; Williams, R.O.; Johnston, K.P. Rapid dissolution of high potency danazol particles produced by evaporative precipitation into aqueous solution. J. Pharm. Sci. 2003. in press.